| Literature DB >> 31214610 |
Xiongjin Chen1, Hui Mai1,2, Xiaoting Chen2, Yujie Cai1, Qiufei Cheng2, Xiaoyi Chen2, Xiaohui Li1, Weihao Fan1, Pei Tang1, Mingqian Ou1, Jingqi Yang1, Yusen Chen2, Lili Cui1.
Abstract
Accumulating evidence reveals that the sirtuin family is involved in the pathology of Parkinson's disease (PD). However, the association between the polymorphisms of the sirtuin gene and the risk of PD remains elusive. Here, we investigated the possible association of nine SIRT1 and SIRT2 SNPs with the risk of PD through a clinical case-control study from the Chinese Han population. Our results showed that rs12778366 in the promoter region of SIRT1 and rs2015 in the 3'untranslated region (3'UTR) of the SIRT2 were significantly associated with the risk of PD. Five SNPs related to SIRT1, rs3740051, rs7895833, rs7069102, rs2273773, and rs4746720 and two SNPs related to SIRT2, rs10410544, and rs45592833 did not show an association with PD risk in this study. Moreover, we found that mRNA level of SIRT2 was upregulated, and mRNA level of SIRT1 was downregulated in the peripheral blood of PD patients compared with healthy controls, and we also observed that SNPs rs12778366 and rs2015 influenced the SIRT1 and SIRT2 expression levels, respectively. Further functional assays suggest that rs2015 may affect the expression of SIRT2 by affecting the binding of miR-8061 to the 3'UTR of SIRT2, ultimately contributing to the risk of PD.Entities:
Year: 2019 PMID: 31214610 PMCID: PMC6535834 DOI: 10.1155/2019/1498034
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
The general clinical data of PD group and control group.
| Clinical data | PD group (n=222) | Control group (n=161) |
|
|---|---|---|---|
| Age (year) | 68.17±10.06 | 66.34 ±7.50 | 0.0581 |
| male /female | 134/88 | 89/72 | 0.3196 |
Frequency distribution of nine SNPs of SIRT1 and SIRT2 gene in PD patients and healthy controls.
| Gene | SNP | Genotype | Allele | Dominant model | Recessive model | ||
|---|---|---|---|---|---|---|---|
| P-value | P-value | P-value | 95%CI | P-value | 95%CI | ||
| SIRT1 | rs3740051 G>A | 0.0967 | 0.7481 | 0.6176 | 0.7381-1.667 | 0.0591 | 0.9504 - 5.346 |
| SIRT1 | rs2273773 C>T | 0.1363 | 0.8568 | 0.0948 | 0.8729 - 4.670 | 0.1456 | 0.4919 - 1.111 |
| SIRT1 | rs7069102 G>C | 0.4880 | 0.7627 | 0.5260 | 0.5312 - 1.382 | 0.5294 | 0.1484 - 2.291 |
| SIRT1 | rs12778366 C>T | 0.0459 | 0.0111 | 0.1670 | 0.0999 - 1.328 |
| 1.0760- 2.668 |
| SIRT1 | rs4746720 C>T | 0.7823 | 0.7894 | 0.9012 | 0.6640 - 1.592 | 0.5460 | 0.7092 - 1.914 |
| SIRT1 | rs7895833 G>A | 0.7928 | 0.7939 | 1.159 | 0.7724 - 1.741 | 0.5360 | 0.2646 - 1.086 |
| SIRT2 | rs2015 G>T | 0.0431 | 0.4590 | 0.4155 | 0.7529 - 1.987 |
| 1.0120 - 2.599 |
| SIRT2 | rs10410544 C>T | 0.3097 | 0.3173 | N.A | N.A | N.A | N.A |
| SIRT2 | rs45592833 G>T | 0.7928 | 0.7939 | N.A | N.A | N.A | N.A |
Figure 1The genotype distribution between the two SNPs and the expression of their corresponding sirtuins in the peripheral blood of PD patients and healthy controls. (a) The distribution area of the nine SNPs in SIRT1 and SIRT2 gene. (b) The mRNA expression level of SIRT1 distribution in the peripheral blood of the PD patient (n=33) and healthy control (n=32). (c) The mRNA expression level of SIRT1 distribution of rs12778366 C/T genotype carriers in the peripheral blood of the PD patient and healthy control. (d) The mRNA expression level of SIRT2 distribution in the peripheral blood of the PD patient (n=31) and healthy control (n=68). (e) The mRNA expression level of SIRT2 and the distribution of rs2015 G/T genotype carriers in the peripheral blood of the PD patient and healthy control. Data represent the mean ± SEM, ∗P<0.05 vs. control group, ∗∗P<0.01 vs. control group.
Figure 2The screening of the target miRNA on the 3′UTR within rs2015 of SIRT2 gene and the influence of rs2015 on the binding efficiency in vitro. (a) Diagram of the prediction of the miRNA-binding site of SIRT2 3′UTR within SNP rs2015. (b, c, d) Luciferase reporter constructs containing SIRT2 3′UTR or its mutants were cotransfected with three corresponding miRNA mimics (miR-4760-5P, miR-8061, and miR-376a) in HEK-293T cells. (e, f) The expression level of corresponding miRNAs after transfected mimics or inhibitors of miRNAs to the SH-SY5Y cell by QRT-PCR assay, respectively. (g, h) The mRNA expression level of SIRT2 with the corresponding miRNAs' intervention in SH-SY5Y cell by QRT-PCR assay, respectively. (i, j) Western blot analysis for SIRT2 expression treated with mimics or inhibitors of the corresponding miRNA in SH-SY5Y cells. Data represent the mean ± SEM of three or four independent experiments. ∗P<0.05 vs. control group, ∗∗P<0.01 vs. control group, ∗∗∗P<0.0001 vs. control group.